AstraZeneca expands AI oncology collaboration with Immunai
AstraZeneca and Immunai have expanded their collaboration, extending a multi-year collaboration in oncology clinical development through 2027. Under the new deal, Immunai is eligible to receive up to $37.5 million over 2026-2027. It marks the third expansion of the partnership between the two companies, building on previous collaborations in oncology… Read More